We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+4.29%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$4.96B
AUM Growth
+$180M
(+3.8%)
Cap. Flow
+$9.65M
Cap. Flow
% of AUM
0.19%
Top 10 Holdings %
Top 10 Hldgs %
16.47%
Holding
683
New
65
Increased
262
Reduced
255
Closed
50
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$53M |
| 2 |
Johnson & Johnson
JNJ
|
+$42.8M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$27.6M |
| 4 |
PepsiCo
PEP
|
+$27.5M |
| 5 |
Mastercard
MA
|
+$24.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GMCR
KEURIG GREEN MTN INC
GMCR
|
+$32.8M |
| 2 |
ADT
ADT Corp
ADT
|
+$23.8M |
| 3 |
Cigna
CI
|
+$21.3M |
| 4 |
First Solar
FSLR
|
+$21.3M |
| 5 |
AET
Aetna Inc
AET
|
+$20M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 27.7% |
| 2 | Financials | 13.24% |
| 3 | Technology | 10.59% |
| 4 | Industrials | 7.94% |
| 5 | Consumer Discretionary | 7.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
Nektar Therapeutics
NKTR
$2.39B
| $3.52M | 0.07% |
21,333
+1,000
| +5% | +$206K |
|
|
EIGR
302
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $3.5M | 0.07% |
411
+55
| +15% | +$481K |
|
303
Walmart Inc
WMT
$891B
| $3.5M | 0.07% |
127,701
-169,626
| -57% | -$4.81M |
|
|
ACHN
304
DELISTED
Achillion Pharmaceuticals
ACHN
| $3.5M | 0.07% |
355,000
+50,000
| +16% | +$624K |
|
|
DRNA
305
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $3.48M | 0.07% |
145,000
+35,000
| +32% | +$787K |
|
306
TechnipFMC
FTI
$29.6B
| $3.46M | 0.07% |
125,620
+112,555
| +862% | +$3.3M |
|
|
PRE
307
DELISTED
PARTNERRE LTD
PRE
| $3.43M | 0.07% |
29,995
-33,454
| -53% | -$3.84M |
|
|
GHDX
308
DELISTED
Genomic Health, Inc.
GHDX
| $3.39M | 0.07% |
111,000
-9,000
| -8% | -$286K |
|
309
The Mosaic Company
MOS
$7.02B
| $3.38M | 0.07% |
73,434
+68,347
| +1,344% | +$3.34M |
|
|
MRTX
310
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $3.34M | 0.07% |
114,000
+44,000
| +63% | +$1.03M |
|
311
Hasbro
HAS
$12.7B
| $3.34M | 0.07% |
+52,739
| New | +$3.1M |
|
312
Entergy
ETR
$53.6B
| $3.29M | 0.07% |
84,764
+76,802
| +965% | +$3.15M |
|
313
Baxter International
BAX
$12B
| $3.26M | 0.07% |
87,600
-9,574
| -10% | -$363K |
|
|
IMGN
314
DELISTED
Immunogen Inc
IMGN
| $3.22M | 0.06% |
360,000
-125,000
| -26% | -$905K |
|
|
MDCO
315
DELISTED
Medicines Co
MDCO
| $3.22M | 0.06% |
115,000
+40,000
| +53% | +$1.12M |
|
316
Cencora
COR
$60.8B
| $3.21M | 0.06% |
28,220
-2,274
| -7% | -$229K |
|
|
AGEN
317
Agenus
AGEN
$251M
| $3.18M | 0.06% |
31,589
+19,361
| +158% | +$1.93M |
|
318
Arbutus Biopharma
ABUS
$875M
| $3.18M | 0.06% |
+182,000
| New | +$3.73M |
|
319
Canadian National Railway
CNI
$78.1B
| $3.18M | 0.06% |
47,442
-5,090
| -10% | -$346K |
|
320
Banco Bradesco
BBD
$38.4B
| $3.15M | 0.06% |
721,947
-76,531
| -10% | -$375K |
|
|
CALA
321
DELISTED
Calithera Biosciences, Inc
CALA
| $3.12M | 0.06% |
+9,500
| New | +$3.38M |
|
|
TWC
322
DELISTED
TIME WARNER CABLE INC NEW COM STK
TWC
| $3.1M | 0.06% |
20,691
-7,720
| -27% | -$1.15M |
|
|
OMED
323
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
| $3.09M | 0.06% |
120,000
+30,000
| +33% | +$761K |
|
|
MON
324
DELISTED
Monsanto Co
MON
| $3.09M | 0.06% |
27,446
-16,976
| -38% | -$2.02M |
|
325
Unum
UNM
$13.7B
| $3.03M | 0.06% |
89,794
-282,968
| -76% | -$9.39M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q1 2015 Portfolio in Review
As of Q1 2015, Candriam SCA held 683 positions worth $4.96B, up 3.8% from $4.78B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Candriam SCA's Q1 2015 filing shows 65 new, 262 increased, 255 reduced and 50 closed positions. Its largest new stake was TOWERS WATSON & CO COM STK CL A (DE): 96,485 shares worth $12.8M. The largest sale was KEURIG GREEN MTN INC, an estimated $32.8M.
By sector, the portfolio is most concentrated in Healthcare at 28% of assets, up from 24% a quarter earlier, followed by Financials and Technology.
- Candriam SCA's largest Q1 2015 buy was TOWERS WATSON & CO COM STK CL A (DE): 96,485 shares worth $12.8M.
- Candriam SCA added most to Amgen in Q1 2015, an estimated $53M increase.
- Candriam SCA's biggest Q1 2015 reduction was KEURIG GREEN MTN INC, cutting an estimated $32.8M.
- Candriam SCA fully exited JP Morgan Alerian MLP Index ETN 5/24/24 in Q1 2015, selling an estimated $19.2M.
- Candriam SCA's ten largest holdings make up 16% of its $4.96B portfolio in Q1 2015.
- Candriam SCA opened 65 new positions and closed 50 in Q1 2015.
- Candriam SCA's portfolio value rose 3.8% quarter-over-quarter to $4.96B.
Based on Candriam SCA's 13F filing for Q1 2015, filed 27 Apr 2015.